VitriVax
VitriVax develops thermostable vaccine technology, maximizing global accessibility with single-shot solutions.
Founded
2017VitriVax develops thermostable vaccine technology, maximizing global accessibility with single-shot solutions.
VitriVax, founded in Boulder, CO, is dedicated to developing innovative vaccine formulation technologies aimed at maximizing global accessibility and utility for both human and animal vaccines. The company's core mission is to eliminate barriers to global vaccination through its proprietary ALTA platform, which makes vaccines thermostable up to 70°C and enables single-shot administration by combining prime and boost doses into one injection. This technology addresses critical challenges in vaccine distribution and storage, particularly in regions with limited cold chain infrastructure.
Notable figures associated with VitriVax include experts in vaccine development and biotechnology, though specific names are not provided. The company has garnered attention for its groundbreaking ALTA platform, which has the potential to revolutionize vaccine logistics and administration worldwide. By making vaccines more accessible and easier to distribute, VitriVax aims to significantly impact public health outcomes, particularly in underserved areas. The company's innovative approach has positioned it as a key player in the global effort to improve vaccination rates and combat infectious diseases.
Companies similar to VitriVax include Solaris Vaccines, Jurata Thin Film, Vaxess Technologies and Altravax.
VitriVax was founded in 2017.
VitriVax's headquarters is located in Boulder, CO, US.
VitriVax's most recent funding round was for $5M (USD) in December 2023.
As of Dec 6, 2023, VitriVax has disclosed funding of $5M (USD). Undisclosed round amounts are excluded.
VitriVax has 25 employees as of Feb 4, 2024.
Altravax
altravax.com
